This volume - like the NATO Advanced Research Workshop on which it is based - addresses the fundamental science that contributes to our understanding of the potential risks from ecological terrorism, i.e. dirty bombs, atomic explosions, intentional release of radionuclides into water or air. Both effects on human health (DNA and systemic effects) and on ecosystems are detailed, with particular focus on environmentally relevant low-dose ranges. The state-of-the-art contributions to the book are authored by leading experts; they tackle the relevant questions from the perspectives of radiation genetics, radiobiology, radioecology, radiation epidemiology and risk assessment.

This book provides new insights into how new biology, and the emergence of "translational" policies to drive the health bioeconomy, is reshaping the innovation ecosystem for new therapies. A key argument is that a broader definition of value (beyond the economic aspects) is needed to understand health innovation in the twenty-first century.

This book, with its 16 chapters, documents the present state of knowledge of the adenosine A receptor. It covers a wide range of information, including data from 3 studies of theoretical, molecular and cellular pharmacology, signal transduction, integrative physiology, new drug discoveries and clinical applications. It fills an important gap in the literature since no alternative source of such information is currently available. Although the A receptor is increasingly being recognized for 3 its increasing number of biological roles throughout the body and many A receptor 3 ligands have proven useful in elucidating peripheral and central pathologies, many issues remain unresolved. Moreover, research activity in this field continues to grow exponentially, resulting in a constant flow of new information. The chapters in this book cover both basic science and the relevant applications and provide an authoritative account of the current status of the field. They have enabled my goal as editor to make "A Adenosine Receptors from Cell Biology to Pharmacology and 3 Therapeutics" an up to date, scientifically excellent, reference source, attractive to basic and clinical scientists alike, a reality. Detailed understanding of the physico-chemical aspects and molecular biology of the A receptor provides a solid basis for its future development as a target for 3 adenosine-based pharmacotherapies (Chapters 2 and 3).

In this book, leading-edge investigators offer effective strategies to improve current antidepressive therapies and suggest molecular, biological, and genetic approaches that will lead to the development of novel antidepressants. The contributors' critical reviews and commentaries illuminate our understanding of the mechanism(s) responsible for antidepressant action. The book's goal is to move beyond current biogenic amine-based concepts and therapies to the development of new and improved antidepressants that are more effective and have a more rapid onset than current.

This book provides a comprehensive overview of chitin biology and chitin metabolism related enzymes. Chitin, the second most abundant biopolymer in nature after to cellulose, is a linear biopolymer composed of -1,4-linked N-acetylglucosamine (GlcNAc), and an essential component in the exoskeletons of insects, mites, ticks and crustaceans, the egg shells of parasitic nematodes, and fungal cell walls. Although some chitin-containing organisms are a threat to human health, food safety and agricultural production, non-chitin containing organisms like humans, mammals and plants have an innate immune response to these hazardous organisms. The book provides researchers and students with information on the recent research advances concerning the biology of chitin-containing organisms as well as cross-talks between chitin-containing and non-chitin-containing organisms. Highlighting chitin remodeling enzymes and inhibitors, it also offers drug developers essential insights into designing specific molecules for the control of hazardous chitin-containing organisms.

Since the subject of high dilution effects is still a subject for debate, this volume provides evidence in support of effects from control clinical studies, clinical records from veteran physicians, controlled experiments on animals and plants, and in vitro tests without any organisms (Chapter II). An overview of the methods for preparing drugs at ultra high dilution is also provided as well as the basic principles of homeopathy, which has been alleviating human suffering through the use of these drugs for several hundred years (Chapter I). Chapter III provides physical basis of high dilutions as evidence from the NMR, IR, UV and fluorescence spectra of those drugs. Since water is used as the diluents media, the structure and dynamics of water polymers in relation to high dilution are discussed in order to facilitate easy comprehension of this physical aspect, the basic principles of spectroscopy are also described. Chapter IV focuses on the mechanism of action of potentized drugs in the living system, discussing the structure of the cell, the plasma membrane, the integral proteins on the membrane, the interaction between these proteins and high dilutions and the manifestations of the therapeutic effects of high dilutions. Some aspects, peculiar to homeopathy, such as the chief miasm psora, and the literalities and time modalities of symptoms and drug action are interpreted from a scientific perspective. Chapter IV ends with a brief discussion on water structures and the origin of life to show the natural evolution of high dilution effects. The book not only helps in understanding the physical basis of high dilutions and their mechanism of action in organisms but provides many new avenues of investigation into this interdisciplinary field of science.

Research of 5-HT2c receptors stretches back twenty-five years, and while much of it has been productive, the past decade of research has been extraordinary in terms of both amount produced and insights gained. It is hardly surprising that 5-HT2c receptor research has grown so fruitful, given that it is a prominent central serotonin receptor subtype widely expressed within the central and the peripheral nervous system and is thought to play a major role in the regulation of numerous behaviors. It has further been shown by experimental and clinical observation that it may represent a possible therapeutic target for the development of drugs for a range of central nervous system disorders. The time, therefore, is more than appropriate to offer the first ever overview of the research of 5-HT2c receptors. Part of the popular and important series, "The Receptors," The 5-HT2c Receptor provides a thorough update of the functional status of the 5-HT2c receptor. It covers the molecular, cellular, anatomical, biochemical and behavioral aspects of this receptor so as to highlight its distinctive regulatory properties and the emerging functional significance of constitutive activity and RNA-editing in vivo. In addition, the book investigates the receptors' therapeutic potential in a range of different diseases, treated individually in separate chapters, including depression, drug abuse, schizophrenia, eating disorders, Parkinson's disease, Prader-Willi Syndrome, Alzheimer's disease and epilepsy. While not exhaustive, this text is a vital tool in understanding the past and inspiring the future of interdisciplinary research on the 5-HT2c receptor.

For physicians, surgeons, and scientists working on cardiovascular disorders, Applications of Biotechnology in Cardiovascular Therapeutics serves as an invaluable reference by collecting the essential writings of Dr. Kewal K. Jain on the topics of biotechnology as they relate to cardiovascular disease. This thorough volume includes such subjects as biotechnology and therapeutic delivery to the cardiovascular system, cell-selective targeted drug delivery, cell and gene therapies, including antisense and RNA interference, cutting-edge gene therapy approaches, as well as personalized cardiology as a way of integrating new technologies into the selection of the best possible treatment for an individual patient. Selected references from recent literature are collected for each chapter, and the text is supplemented by a variety of useful tables and figures. Comprehensive and up-to-date, Applications of Biotechnology in Cardiovascular Therapeutics will be tremendously useful for those working in life sciences and the pharmaceutical sciences, and the inclusion of some basics of cardiovascular diseases will greatly benefit nonmedical readers as well.

Paul H. Axelsen concisely summarizes all the essential medical data concerning the leading antimicrobials used in fighting infectious diseases and clearly illustrates their mechanisms of action. The agents described range from antibacterial and antifungal to antiparasitic and antiviral agents, and include immunomodulators and immunizing agents. For each drug discussed, the book allows rapid access to the essential facts concerning its structure and mechanism of action, the spectrum of its activity, its pharmacokinetics, its adverse effects, and its resistance. This book provides medical students, physicians, and allied health professionals with rapid access to the core principles of antimicrobial pharmacology, and a foundation for decisions about the use of antimicrobials in daily practice.

Cocaine has been a socio-medical problem for centuries. In the United States, the first cocaine epidemic occurred between the 1880s and the 1920s. In the 1960s shortages of heroin as well as government programs to stop the smuggling of marijuana may have stimulated the use of cocaine as a substitute. With the development of crack, cocaine became available at a price that made it accessible to virtually anyone. Today, the long-term effects of crack are just beginning to be felt, especially among children born of users. Treatment of cocaine abuse has traditionally been non-pharmacological, although beginning with the 1980s, various drugs have been used to decrease cocaine craving. This bibliography contains more than 600 references, spanning a century of research and writing. Source publications, all of which are annotated, include books, articles, conference proceedings, dissertations, and government publications. The material is organized within four subject-oriented chapters, and alphabetically within each chapter. Author and subject indexes provide additional access. In addition, Miletich includes appendixes on common names for cocaine, videocassettes about the drug, and a timeline. The work will be of value to researchers as well as social workers, psychologists, and others working in the substance abuse field.

This book is based on the proceedings of the symposium entitled "Di rected Drug Delivery: A Multidisciplinary Problem," which was held in Lawrence, Kansas on October 17-19, 1984. The purpose of the sym posium and this book is to focus on the multidisciplinary nature of drug delivery. Development of a successful drug delivery system re quires contributions from various scientific disciplines, including pharmaceutical chemistry, analytical chemistry, medicinal chemistry, biochemistry, pharmacology, toxicology, and clinical medicine. The contents of this volume illustrate the importance of the various disci plines in identifying the problems and approaches for the develop ment of a rational and effective drug delivery system. Thus the infor mation provided herein will be of value not only to the pharmaceutical chemists who are responsible for dosage form design, but also to the pharmacokineticists, pharmacologists, and clinicians involved in bio logical evaluation of drug delivery systems. The volume should also be of interest to the analytical chemists who must provide technology to quantitcltively evaluate drug delivery. Additionally, this work will also interest the biochemists and medicinal chemists involved in drug dis covery, since the drug delivery system often plays a major role in determining the success or failure of a new drug entity. Each speaker at the symposium was requested to contribute a chapter reviewing the contribution of their major discipline to the de velopment of a successful drug delivery system."

Understanding an individual's genetic makeup is the key to creating personalized drugs with greater efficacy and safety, and pharmacogenomics aims to study the complex genetic basis of inter-patient variability in response to drug therapy. Based upon the success of its first edition, the second edition of Pharmacogenomics: Methods And Protocols aims to continue providing readers with high-quality content on the most innovative and commonly adopted technologies in the field of pharmacogenomics as presented by experts in the field. Broken into several sections, this detailed volume examines techniques for interrogating variation in human genes and genomes, functional assessment of genetic variation, both in vitro and in vivo, as well as tools for translation and implementation of pharmacogenetic markers. Written in the highly successful Methods in Molecular Biology (TM) series format, chapters include introductions to the respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls. Comprehensive and thoroughly updated, Pharmacogenomics: Methods And Protocols, Second Edition serves as an essential reference and an invaluable source on the latest information in this field.

This book discusses the relationship between cellular immunity and tryptophan metabolism, as well as its products, serotonin and melatonin, in the development of several diseases and reappraises the common signal transduction pathways of the neurodegenerative diseases, carcinogenesis, immune tolerance, inflammation, hypersensitivity reactions, neuropsychiatric disorders, in addition to bacterial tryptophan biosynthesis and novel antimicrobials. Tryptophan Metabolism: Implications for Biological Processes, Health and Disease presents fundamental information on tryptophan related metabolic pathways and metabolites, implications of these products for specific biological processes, diseases and conditions. This book focuses on effects of tryptophan metabolites on human health and will appeal to researchers, clinicians and students within this field.

The volumes of this classic series, now referred to simply as "Zechmeister" after its founder, L. Zechmeister, have appeared under the Springer Imprint ever since the series inauguration in 1938. The volumes contain contributions on various topics related to the origin, distribution, chemistry, synthesis, biochemistry, function or use of various classes of naturally occurring substances ranging from small molecules to biopolymers. Each contribution is written by a recognized authority in his field and provides a comprehensive and up-to-date review of the topic in question. Addressed to biologists, technologists, and chemists alike, the series can be used by the expert as a source of information and literature citations and by the non-expert as a means of orientation in a rapidly developing discipline.

This treatise had its origins in the authors' strong opinion that the discovery of new drugs, especially of innovative therapeutic agents, really does not happen as a spontaneous sequel to investiga tive research, no matter how penetrating such research may be. Rather, it seemed to us that the discovery of innovative therapeutic agents was a very active process, existing in and of itself, and demanding full attention-it was not simply a passive, dependent by-process of investigative research. And yet, many researchers some close confreres of the authors, others more distant-believed otherwise. We felt that their view reflected unrealistic thinking and that reality probably lay closer to what Beyer" maintained: We are taught to believe that if we can understand a disease it should be easy enough to figure out, say, the molecular configuration of a definitive receptor mechanism somewhere along the line and to design a specific drug . . . . And so we start out to understand the disease but never get around to doing much about therapy. The authors very soon realized that there was essentially no quantitive information available on just where and how innovative therapeutic agents were discovered. There were only anecdotal accounts, and these were able to be selected and presented in ways that could be used to defend any point of view."

This volume is an English translation of Overton's monograph on structure-activity relationships regarding anaesthetic action and toxicity. This book has been cited widely by scientists studying the correlation of biological activity with partition coefficients and the mechanism of anaesthesia. Although the original monograph was published in 1901, it should still be of value to modern toxicologists, particularly those involved in the development of quantitative structure-toxicity relationships and the predictive limitations of such models. Introductory chapters by Lipnick, Miller and Winter emphasize the importance of this text. This book should be of interest to anaesthetists, pharmacologists, toxicologists, medical and organic chemists and pharmaceutical historians.

Important clinical issues as the outcome of long term treatment with antidepressants, the time of onset of the antidepressant response and the limitations of the antidepressants currently available are covered in this monograph. Leading researchers in the area of clinical and experimental psychopharmacology critically assess the progress in their specialist fields. The mechanisms of action of antidepressants are considered, followed by clinical research into the role of the hypothalamic-pituitary-adrenal axis and the immune system in the biology of depression and in response to treatment. The final chapter deals with the important chemical entities now undergoing development as antidepressants. The purpose of this monograph is not only to inform but also to stimulate research into the biology of depression and the mechanisms behind the action of effective antidepressants. This monograph is of interest to psychiatrists, psychologists, pharmacologists, neuroscientists and endocrinologists.

During the past several years tremendous advancements have been made in the field of pharmacology and therapeutics. While new therapeutic strategies are coming up, old ones are being improved by modifications, or being replaced with newer ones. The major topics covered in this book include: endothelins, current topics in cardiovascular research, molecular pharmacology, recent developments in cancer research, antioxidants, oxidants and human disease, herbal drugs, developments in neuropharmacology, myelin biology and demyelinating disease, pharmacovigilance, role of cytokines in health and disease, ocular pharmacology, detoxification of xenobiotics-biotransformation and transport, and several other topics of current interest. The aim of this book is to fulfill the needs of the basic and clinical researchers as well as the students, particularly related to areas of current interest in pharmacology and therapeutics.

This volume provides a comprehensive review of resistance induced by photodynamic therapy (PDT) in tumor cells. Understanding the underlying mechanisms in this process leads to the improvement of therapeutic modality, in combination with chemotherapy, immunotherapy, and radiotherapy. Photodynamic therapy is a minimally invasive therapeutic procedure that can exert a selective or preferential cytotoxic activity toward malignant cells. The procedure involves administration of an intrinsically non-toxic photosensitizing agent (PS) followed by irradiation at a wavelength corresponding to a visible absorption band of the sensitizer. In the presence of oxygen, a series of events lead to direct tumor cell death, damage to the microvasculature, and induction of a local inflammatory reaction. Studies reveal that PDT can be curative, particularly in early stage tumors and this volume explores the potential of PDT, but also reveals strategic approaches to overcome resistance in tumor cells.

Over the past twelve years, the Centre for Medicines Research has held a series of Workshops on a number of topics related to the drug discovery and development process. The major objective of these Workshops has been to provide an international forum for regula tory, academic and industry representatives to debate together, and suggest solutions to, specific problems. The meeting reported in this volume represents a departure from this approach, in that the par ticipants were drawn largely from the pharmaceutical industry. Senior clinicians, pharmacologists and toxicologists from companies in Europe, the USA and Japan met in May 1994 to discuss a scientific rationale for the conduct of toxicity studies to support the clinical development of new medicines, and to begin to work towards an industry consensus. Achievement of such a consensus is seen as an important step in the process leading towards international harmon isation of the recommendations on the timing of toxicity studies in relation to clinical trials."